Novartis AG (ADR) (NYSE:NVS) has been downgraded to Sell in a statement by Zacks Investment Research earlier today.
- Updated: November 29, 2016
Having a price of $69.03, Novartis AG (ADR) (NYSE:NVS) traded -0.16% lower on the day. With the last stock price down -12.04% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.03% over the same period. NVS has recorded a 50-day average of $72.79 and a two hundred day average of $78.41. Trade Volume was down over the average, with 1,565,900 shares of NVS changing hands under the typical 2,669,880
Zacks Investment Research has downgraded Novartis AG (ADR) (NYSE:NVS) to Sell in a statement released on 11/29/2016.
On 1/19/2016, Leerink Swann released a statement about Novartis AG (ADR) (NYSE:NVS) dropped the target price from $110.00 to $98.00 that suggested an upside of 0.20%.
Recent Performance Chart
Novartis AG (ADR) has PE ratio of 24.32 with a one year low of $67.28 and a one year high of $88.49 and has a market capitalization of $0.
A total of 4 brokerages have issued a ratings update on Novartis AG (ADR). Two brokerages rating the company a strong buy, one brokerage rating the company a buy, one brokerage rating the company a hold, zero brokerages rating the company a underperform, and finally zero brokerages rating the company a sell with a 12-month price target of $94.50.
General Company Details For Novartis AG (ADR) (NYSE:NVS)
Novartis AG is a holding company. The Company specializes in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals, including eye care products. Its portfolio includes medicines, eye care and generic pharmaceuticals. The Company's segments include Pharmaceuticals, Alcon and Sandoz. Its Pharmaceuticals segment is engaged in researching, developing, manufacturing, distributing and selling patented prescription medicines in the therapeutic areas, such as oncology, cardio-metabolic, immunology and dermatology, retina, respiratory, neuroscience and established medicines. Its Alcon segment is engaged in developing, manufacturing and selling eye care products across the world. Its Sandoz segment is engaged in developing, manufacturing and marketing generic pharmaceutical products, follow-on biopharmaceutical products known as biosimilars and drug substances that are not protected by valid and enforceable third-party patents.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.